Overview
1. Lung cancer/new treatment approaches.
2. Clinical trials of hematopoietic growth factors, biological agents and targeted drug development.
3. Cancer in the elderly and supportive care
Accomplishments
1. Lead Investigator of the U. S. multicenter, randomized trial of Filgrastim (G-CSF, Neupogen) to reduce the morbidity of chemotherapy-related neutropenia, leading to FDA approval 2/91.
2. Lead Investigator of the U. S. multicenter, randomized trial of Vinorelbine (Navelbine) in treatment of patients with advanced non small cell carcinoma of lung (NSCLC), leading to FDA approval 12/94.
3. Principal Investigator in initial phase I clinical trials of stem cell factor (SCF), megakaryocyte growth and development factor (MGDF), pegylated granulocyte-colony-stimulating factor and other novel hematopoietic growth factors.
2. Clinical trials of hematopoietic growth factors, biological agents and targeted drug development.
3. Cancer in the elderly and supportive care
Accomplishments
1. Lead Investigator of the U. S. multicenter, randomized trial of Filgrastim (G-CSF, Neupogen) to reduce the morbidity of chemotherapy-related neutropenia, leading to FDA approval 2/91.
2. Lead Investigator of the U. S. multicenter, randomized trial of Vinorelbine (Navelbine) in treatment of patients with advanced non small cell carcinoma of lung (NSCLC), leading to FDA approval 12/94.
3. Principal Investigator in initial phase I clinical trials of stem cell factor (SCF), megakaryocyte growth and development factor (MGDF), pegylated granulocyte-colony-stimulating factor and other novel hematopoietic growth factors.
Current Duke Appointments & Affiliations
George Barth Geller Distinguished Professor Emeritus for Research in Cancer
·
2026 - Present
Medicine, Medical Oncology,
Medicine
Professor Emeritus of Medicine
·
2026 - Present
Medicine, Medical Oncology,
Medicine
Member of the Duke Cancer Institute
·
1974 - Present
Duke Cancer Institute,
Institutes and Centers
Recent Scholarly Works
Perioperative Durvalumab for Resectable Non-Small Cell Lung Cancer: Updated Outcomes From the Phase III AEGEAN Trial.
Journal article J Clin Oncol · August 28, 2026 In AEGEAN, perioperative durvalumab plus neoadjuvant chemotherapy, versus neoadjuvant chemotherapy alone, significantly improved event-free survival (EFS) and pathologic complete response in patients with resectable non-small cell lung cancer (R-NSCLC), wi ... Full text Link to item CiteNovel Antibodies for Managing Cachexia.
Journal article Annu Rev Med · August 4, 2026 Cachexia is a complex, multifactorial syndrome driven by anorexia and systemic inflammation, ultimately resulting in a catabolic state characterized by weight loss, decreased muscle mass, and impaired physical function. Many chronic comorbidities are impli ... Full text Link to item CiteFunctional Outcomes and Quality of Life for Patients With Cachexia and Solid Tumour Cancers: Findings of a Systematic Literature Review.
Journal article J Cachexia Sarcopenia Muscle · August 2026 BACKGROUND: Cachexia, a complex multifactorial syndrome characterized by loss of skeletal muscle mass, is common in cancer and impacts treatment response, quality of life (QoL) and survival. No effective therapy is currently available. This report summariz ... Full text Link to item CiteRecent Grants
The Duke University - Duke Cancer Institute National Clinical Trials Network Lead Academic Participating Site (UG1) Support Grant
ResearchCo Investigator · Awarded by National Institutes of Health · 2019 - 2032A Phase III, Double-blind, Placebo-controlled, Multi-center International Study of Durvalumab plus Chemotherapy Prior to Surgery Followed by Durvalumab Post-surgery Versus Placebo plus Chemotherapy Prior to Surgery Followed by Placebo Post surgery
Clinical TrialPrincipal Investigator · Awarded by AstraZeneca Pharmaceuticals, LP · 2019 - 2026Alliance/NCORP Parent - Non Federal
Clinical TrialPrincipal Investigator · Awarded by Alliance NCTN Foundation · 2020 - 2026View All Grants
Education
Ohio State University ·
1974
M.D.